Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iris-2: Ibodutant in IBS-D
2010-018300-85Phase 2Completed
- Sponsor
- Menarini Group
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibodutant in Diarrhea-predominant irritable bowel syndrome (IBS-D) (4 arms), sponsored by Menarini Group. Primary endpoint: Primary response for relief of overall IBS symptoms and abdominal pain/discomfort. Started May 2010; status: completed.
02
Drugs
ibodutant
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2010-018300-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018300-85.